共 35 条
- [21] Evaluating No Evidence of Disease Activity (NEDA) in Patients With Relapsing Multiple Sclerosis: Post Hoc Analysis of the Phase 3 RADIANCE and Open-Label Extension Studies of OzanimodMULTIPLE SCLEROSIS JOURNAL, 2022, 28 (2_SUPPL) : 11 - 12Kappos, L.Comi, G.Selmaj, K. W.Steinman, L.Bar-Or, A.Arnold, D. L.Hartung, H. P.Montalban, X.Havrdova, E. K.Pachai, C.Sheffield, J. K.Cheng, C. Y.Silva, D.Vaile, J.Morello, J. P.Cohen, J. A.Cree, B. A. C.
- [22] Iron Uptake from Ferric Maltol in Patients with Iron Deficiency with or without Anemia: Post Hoc analysis of a Multicenter, Open-Label, Randomized, Phase 1 Clinical StudyBLOOD, 2023, 142Howaldt, StefanieCody, MichaelMitchell, Jacqueline A.
- [23] Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal seizures: post hoc analysis of a phase III trial and open-label extension studyTHERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2023, 16Trinka, EugenRocamora, RodrigoChaves, JoaoKoepp, Mathias J.Rueegg, StephanHoltkamp, MartinMoreira, JoanaFonseca, Miguel M.Castilla-Fernandez, GuillermoIkedo, Fabio
- [24] DEPRESSIVE SYMPTOMS IMPROVE WITH 1-YEAR ESLICARBAZEPINE ACETATE TREATMENT: A POOLED ANALYSIS OF 3 OPEN-LABEL EXTENSIONS OF PHASE III STUDIES IN PATIENTS WITH PARTIAL-ONSET SEIZURESEPILEPSIA, 2010, 51 : 117 - 117Cramer, J.Hodoba, D.Ben-Menachem, E.Elger, C.Gil-Nagel, A.Maia, J.Nunes, T.Soares-da-Silva, P.
- [25] Adverse effect of docetaxel versus surveillance after radical prostatectomy for high risk prostate cancer: Post-hoc analysis of the prospective randomized, open-label phase III SPCG 12 trial.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)Ahlgren, Goran M.Borre, MichaelSengelov, LisaTammela, Teuvo L. J.Kellokumpu-Lehtinen, PirkkoSverrisdottir, AsgerdurIversen, Jon Reidar
- [26] Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuriaANNALS OF HEMATOLOGY, 2024, 103 (01) : 5 - 15Schrezenmeier, HubertKulasekararaj, AustinMitchell, Lindsayde Latour, Regis PeffaultDevos, TimothyOkamoto, ShinichiroWells, RichardPopoff, EvanCheung, AntoinetteWang, AliceTomazos, IoannisPatel, YogeshLee, Jong Wook
- [27] Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuriaAnnals of Hematology, 2024, 103 : 5 - 15Hubert SchrezenmeierAustin KulasekararajLindsay MitchellRégis Peffault de LatourTimothy DevosShinichiro OkamotoRichard WellsEvan PopoffAntoinette CheungAlice WangIoannis TomazosYogesh PatelJong Wook Lee
- [28] Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc AnalysisARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2798 - 2801Gladman, DafnaNash, PeterMease, Philip J.FitzGerald, OliverMasri, Karim R.Duench, StephanieJane Cadatal, Mary
- [29] Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysisARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)Gladman, Dafna D.Nash, PeterMease, Philip J.Fitzgerald, OliverDuench, StephanieCadatal, Mary JaneMasri, Karim R.
- [30] Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 TrialDiabetes Therapy, 2022, 13 : 1161 - 1174Xiang YanChen FengYing LouZhiguang Zhou